Podcasts about jp morgan healthcare conference

We love to hear from our listeners. Send us a message. In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission. It's a timely and important conversation that explores how these selective inhibitors could provide effective pain relief without the addiction risks and side effects of traditional opioids. In addition to the social and medical implications of Latigo's work, we discuss investor perceptions about pain management as a commercial opportunity and how Latigo is differentiating from traditional approaches by focusing on safety and tolerability rather than just efficacyThe 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Miruna Sasu, CEO of COTA, has been labeled as a disrupter in the industry. In this episode, she discusses the challenges of stringent inclusion and exclusion criteria of clinical trials. She also dives into her main takeaways from this year's JP Morgan Healthcare Conference and Scope Summit around exits and investment in women's health.Host⁠⁠⁠Lori Ellis⁠⁠⁠, Head of Insights, BioSpaceGuests⁠Miruna Sasu⁠, President and CEO, COTADisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms. We learn the differences between royalty financing and equity-based funding, how the model addresses traditional risk in biotech financing, the evolution of XOMA's business model, and much more. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

We love to hear from our listeners. Send us a message. Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

We love to hear from our listeners. Send us a message. Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges. Along the way, we cover innovations in distributed manufacturing, non-viral gene delivery, and the importance of collaboration with academia to make these transformative therapies widely available.The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Citeline's expert panel of reporters and analysts unpack the biggest deals, trends, and innovations from the JP Morgan Healthcare Conference. Discover what these developments mean for you and the future of the industry in 2025 and beyond.

In this episode of The Harry Glorikian Show, host Harry Glorikian welcomes back Jeff Elton, CEO of Concert AI, to discuss the latest advancements in AI-driven healthcare solutions. They reflect on the recent JP Morgan Healthcare Conference, highlighting the optimism surrounding AI's role in transforming drug development and oncology. Jeff shares insights into Concert AI's innovative data ecosystems, partnerships, and the introduction of Kera, an AI platform designed to enhance clinical decision-making. The conversation also explores the challenges and opportunities in the evolving landscape of healthcare technology, emphasizing the importance of collaboration and adaptability in the face of rapid change.Takeaways:The JP Morgan Healthcare Conference indicated a positive outlook for the industry.AI is becoming a central theme in healthcare discussions.Concert AI is developing a comprehensive data ecosystem for oncology.The introduction of agentic AI models is set to revolutionize data processing.Collaboration with NVIDIA is enhancing Concert AI's capabilities.Kera is a significant advancement in AI-driven healthcare solutions.The future of drug development will rely heavily on AI and data analytics.Healthcare organizations must adapt to the rapid pace of technological change.Building partnerships is crucial for addressing healthcare fragmentation.The integration of AI in clinical trials can significantly reduce timelines.Chapters 00:00 The Annual Healthcare Pilgrimage03:19 Optimism in the Pharma Industry06:07 The Rise of AI in Healthcare10:03 Concert AI's Evolution and Innovations15:10 2024: A Standout Year for Concert AI18:55 Balancing Growth and Innovation22:33 Scaling Across Therapeutic Areas26:26 The Future of Collaborations in Healthcare28:37 Integrating Immune Status and Data Collaboration31:04 Introducing Kera AI: The Future of Data Management35:24 Innovations in Clinical Trials and Data Solutions40:16 Rethinking Drug Development: Digital Twins and AI42:36 Navigating Market Shifts and Talent Challenges54:02 The Future of Concert AI and Healthcare Solutions  

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. Anastasiou discusses the in-house manufacturing quality advantage, how building that capacity opened the door to important partnering opportunities, the company's preparation for clinical trials and IND submissions, and more. From mastering in-house manufacturing to forging strategic partnerships, Capsida aims to redefine genetic medicine.The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

The JP Morgan Healthcare Conference remains one of the most influential events for the life sciences sector, setting the stage for major deal-making, investment trends, and strategic shifts that will define the year ahead. Keen to capture all the key trends and talking points from this year's event, pharmaphorum editor-in-chief, Jonah Comstock, hit the ground running in Philadelphia, live blogging key sessions and interviewing experts to find out what industry insiders foresee for 2025. In this special extended episode of the pharmaphorum podcast, Jonah sits down with Deep Dive editor, Eloise McLennan, to break down the key themes and takeaways from this year's event. From the impact of the new Trump Administration on research and development to advancements in brain health, PBM reform, and the evolving role of GenAI in clinical trials, they explore the discussions and developments set to shape pharma's trajectory in 2025 and beyond. Plus, hear exclusive interviews from experts, including: Catherine Owen Adams from Acadia Pharmaceuticals on trends and innovations in brain health NKarta's Paul Hastings discusses natural killer cells and developments in cell and gene therapies Evidation's Phil Johnson on the role of real world data in drug development Grove AI's Tran Le and Sohit Gatiganti on the immense potential of AI in audio for clinical trials You can listen to this episode, as well as previous episodes of the pharmaphorum podcast, in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discusses the balance between promising advances in T-cell therapy and the challenges associated with navigating a biotech from platform development to lead candidate status -- including staffing up for and funding the journey. Don't miss this episode, recorded in-person in San Francisco. The 2025 BoB@JPM series is supported by Aslton & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

In this episode, Fiona and Manasi discuss the largest talking points at the 2025 JP Morgan Healthcare Conference, including 2025's investment outlook in biotech, the BIOSECURE Act, and GLP-1 agonists. Find us on LinkedIn: https://www.linkedin.com/company/globaldatastrategicintelligence/ To understand how to use our Themes product please contact us: customersuccess.strategic@globaldata.com +44 (0) 207 406 6764    Host: Carolina Pinto Guest: Fiona Barry, Manasi Vaidya

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Dexcom updates investors on its 15-day sensor, TrialNet marks a big anniversary, Beta Bionics goes public, NFL fans support Mark Andrews and much more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Couple of quick updates from the JP Morgan Healthcare Conference. Dexcom's CEO Kevin Sayer expects to launch a 15-day sensor in the second half of the year. That's in front of the FDA right now. Competitor Abbott currently has 15-day sensors with its Freestyle Libre 2 Plus and Freestyle Libre 3 Plus devices, which the FDA cleared in 2023. Sayer also talked about expanded insurance coverage for the G7, to include more people with type 2. They haven't pursued that with Stelo, the OTC version of their sensors. The company has begun work on a next-generation CGM. Sayer said the sensor will be smaller, less expensive and include better electronics. Dexcom is also studying new sensor probes, one of which can support multiple analytes, such as measuring lactate or ketones in addition to insulin.   https://www.medtechdive.com/news/dexcom-ceo-stelo-otc-strategy-jp-morgan/737424/ XX TrialNet reaches a big milestone – more than a quarter million people have learned their risk of developing T1D through screening. TrialNet screening is available to family members of those diagnosed with T1D. Having a family history of the disease places individuals at a 15 times greater risk than those with no family members with T1D. Over the course of VUMC's 18 years participating in the program, the community of T1D patients has become increasingly more engaged with research efforts. More than ever, there is an eagerness to give back to others by participating in clinical trials that could help revolutionize care for those diagnosed with or at risk of developing T1D. In such trials, TrialNet typically takes drugs already shown to be effective in treating other autoimmune diseases and seeks to determine their efficacy in treating, delaying or preventing T1D.   Spencer Mannahan, a 10-year-old patient at Monroe Carell Jr. Children's Hospital at Vanderbilt, is participating in a TrialNet study that is looking to determine whether a treatment regimen using both rituximab and abatacept can preserve insulin production in patients newly diagnosed with T1D. Russell, one of the PIs for the study (Protocol TN-25), also treated Spencer's father, Zach, when he was diagnosed with T1D as a child. She enrolled in a different TrialNet study (Protocol TN-31) examining the effect of abrocitinib and ritlecitinib on insulin production in newly diagnosed individuals. While the possibility exists that her insulin production could be preserved, O'Neal joined the study because it presented an opportunity to make a positive impact on future patients.     These clinical trials support TrialNet's goal of a future without T1D. Research is underway on new methods of blocking the advance of T1D in patients with diabetes-related antibodies. One study will investigate whether T cells that have been activated against insulin can be specifically targeted, rather than issuing a treatment that targets all the body's T cells (thus rendering the patient immunocompromised).   TrialNet, the largest clinical trial network assembled to change the course of Type 1 diabetes, is funded by the National Institutes of Health through grant number NCT00097292.   For more information about screening for Type 1 diabetes risk if it runs in your family, contact info@trialnet.org, visit www.trialnet.org, or contact the Vanderbilt Type 1 Diabetes TrialNet Program at 615-936-8638. https://news.vumc.org/2025/01/22/milestone-in-vumc-affiliated-diabetes-screening-and-research-program-underscores-impact-of-clinical-trials/   XX Another study links air pollution to type 2 diabetes. This is from Wayne State University, and established a robust association between exposure to benzene, a prevalent airborne volatile organic compound, and insulin resistance in humans across all ages. “In this study, we exposed mice to benzene to see how it affects their blood glucose levels and energy expenditure,” she explained. “Our research revealed that within seven days of exposure, they developed high blood glucose insulin levels.” https://today.wayne.edu/medicine/news/2025/01/23/study-links-air-pollution-exposure-to-type-2-diabetes-susceptibility-65321 XX Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone. The researchers say this study provides a practical strategy to achieve remission for patients with early type 2 diabetes. As well as helping to lower blood sugar levels, SGLT-2 inhibitors can also lead to weight loss, but their effect alongside calorie restriction on diabetes remission has not yet been investigated in a randomised controlled trial.   To address this, researchers carried out a trial involving 328 patients with type 2 diabetes of less than six years' duration at 16 centres in mainland China from 12 June 2020 to 31 January 2023.   Participants were aged 20-70 years with a body mass index (BMI) greater than 25 and were not taking any anti-diabetic medication other than metformin. https://www.news-medical.net/news/20250123/Dapagliflozin-and-calorie-restriction-show-higher-remission-rates-in-type-2-diabetes.aspx XX Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its artificial pancreas system for people with Type 1 diabetes. That's as we're recroding, it's likely they will have begun trading on the NASDAQ by now.. the ticker is BBNX. Beta Bionics' iLet system was first cleared by the FDA for people ages six and up with Type 1 diabetes in May 2023. The Fierce Medtech Fierce 15 winner has since expanded its blood sugar sensor compatibility to include Abbott's FreeStyle Libre and Dexcom's G6 and G7 platforms. The company also said it plans to pursue new clinical studies and an FDA clearance that would enable the iLet's use among people with Type 2 diabetes. The ultmite goal is to have a dual-chambered pump with both insulin and glucagon.. but I didn't find anything about that in the articles about this IPO.. I followed up with Beta Bionics and they told me that the dual chambered pump is still very much the goal. Not sure why most of the publications left that out.. but good to hear. https://www.fiercebiotech.com/medtech/artificial-pancreas-maker-beta-bionics-aims-raise-120m-nasdaq-ipo XX Large new study estimates the size of the current US population with type 1 diabetes and project growth over the next ten years. They say about 2 million live with type 1.. about 1.79 million adults and 290-thousand children. Growth in the ten years is predicted to be about 10% https://jheor.org/article/124604 XX The American Diabetes Association® (ADA) teams up with Xeris Pharmaceuticals® makers of Gvoke – ready to use emergency glucagon. It is estimated that up to 46% of people with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event each year.2 The ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net. https://www.prnewswire.com/news-releases/the-american-diabetes-association-and-xeris-pharmaceuticals-announce-national-collaboration-to-provide-life-saving-hypoglycemia-education-and-awareness-302355703.html XX XX Wearing a CGM makes pharmacy students better at counseling patients. New study randomly assigned students to wear a CGM during lab sessions.. those who did had a higher average counseling score during the encounter with a patient and a higher overall confidence score. There was also a statistically significant positive correlation between average confidence and average empathy, and empathy and counseling performance. https://www.drugtopics.com/view/hands-on-cgm-training-helps-student-pharmacists-prepare-for-career XX Mark Andrews Bills Mafia Baltimore Ravens tight end Mark Andrews received a host of negative attention after flubbing a potential game-tying two-point conversion in Sunday night's loss to the Buffalo Bills.   In the face of the online rage, Bills Mafia is again showing some support.   Bills fan Nicholas Howard kicked off a GoFundMe to back Breakthrough T1D, a global Type 1 diabetes research organization that Andrews has supported.   "As many of you know, Ravens TE wasn't able to catch the game-tying 2-point conversion and upset Ravens fans," Howard wrote. "On top of that, the TE has been receiving death threats and nasty comments after his performance last night. We want Bills Mafia to donate to Marks charity for [Type 1] diabetes."   As of Wednesday morning, the fund raised more than $50,000 for the charity.   Related Links Lamar Jackson, Ravens bemoan missed opportunities in loss to Bills, defend Mark Andrews Ravens WR Zay Flowers: Missing 2024 playoff run due to injury 'took a little toll on me' Biggest winners and losers from Sunday's Divisional Round NFL playoff games The Ravens thanked Bills fans for supporting Andrews.     "Shout out to Bills Mafia for showing support to our guy Mark Andrews and donating to the [BreakthroughT1D] organization, which works towards curing and improving the lives of those dealing with Type 1 diabetes," the club posted.   Andrews was diagnosed with Type 1 diabetes as a child, an autoimmune disease for which there is currently no cure. He's one of several NFL players diagnosed with Type 1 -- Kansas City Chiefs tight end Noah Gray is another.   "Breakthrough T1D [formerly JDRF] greatly appreciates the generosity of the Buffalo Bills community and the many fans who were compelled to donate after Sunday's game," the organization said in a statement to ESPN's Alaina Getzenberg. "These donations will support research and advocacy on behalf of the 1.6 million Americans who, like Mark Andrews, live with type 1 diabetes."   It's not the first time that Bills fans have donated to the cause of a non-Buffalo player. Back in January 2018, Buffalo fans famously donated to the charity of former Cincinnati Bengals quarterback Andy Dalton after his win over Baltimore helped Buffalo make its first playoff appearance in nearly two decades. Over and over again, Bills Mafia has shown it will support a good cause when some spew hate. https://www.nfl.com/news/bills-fans-supporting-ravens-te-mark-andrews-after-drop-by-donating-to-type-1-diabetes-research

In this episode, Amber Walsh, Partner at McGuireWoods LLP, shares her expertise on the evolving landscape of healthcare private equity. Here, she discusses trends highlighted at the JP Morgan Healthcare Conference, insights into deal dynamics, the role of private credit, and the impact of AI and new growth strategies on the healthcare sector.

In this episode, Amber Walsh, Partner at McGuireWoods LLP, shares her expertise on the evolving landscape of healthcare private equity. Here, she discusses trends highlighted at the JP Morgan Healthcare Conference, insights into deal dynamics, the role of private credit, and the impact of AI and new growth strategies on the healthcare sector.

The streets around San Francisco's Union Square were a bit more crowded today as the City hosted its first major conference of the new year. The JP Morgan kicked off at the Westin St. Francis earlier this week and it runs through Thursday. For more on the economic impacts on the conference, KCBS Radio news anchors Patti Reising and Bret Burkhart spoke with KCBS Insider Phil Matier.

GE HealthCare President and CEO Peter Arduini discusses the company’s $1 billion imaging deal with Sutter Health and the future of AI in the health-care industry. He speaks with Bloomberg's Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco.See omnystudio.com/listener for privacy information.

Some of the most popular names in the market seeing some major moves. How the recent drops in Nvidia, Tesla, and Bitcoin fare from here, and how banks are setting up ahead of earnings season. Plus The prognosis on the health care space, as the industry's top execs convene at the JPMorgan conference in San Francisco. How our traders are handling the moves in the space's biggest names.Fast Money Disclaimer

Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market and supply shortages of the drug Adderall. He speaks to Bloomberg's Katie Griefeld from the JPMorgan Healthcare Conference.See omnystudio.com/listener for privacy information.

Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.See omnystudio.com/listener for privacy information.

One of Wall Street's most successful quant fund managers, AQR Founder & CIO Cliff Asness joins Money Movers with his outlook for the markets, how he's thinking about value versus growth and what another Trump administration means for stocks. Then the CEO of drugmaker GSK is live from the JPMorgan Healthcare Conference in San Francisco, in her first interview since announcing a billion dollar plus deal in the cancer space. And the CEO of Edison International, the parent company of one of California's biggest utilities joins the show with more details on what's being done to contain the LA wildfires and how the blazes are impacting the future of the company.

IR Department's managing director Jane Lowe talked with Proactive's Tylah Tully about AGM season and the critical role annual general meetings play for shareholders and companies alike. Lowe highlighted the importance of AGMs as a platform for shareholder engagement, noting they offer shareholders a rare chance to vote on essential company matters and interact directly with the board and executive team. “The AGM can be an excellent platform for engaging with potential and existing shareholders,” Lowe explained, emphasizing the value of well-prepared resolutions and open communication. Lowe walked through the AGM process, from preparing resolutions and understanding shareholder preferences, to ensuring CEOs and board members are prepared for Q&A sessions. In addition, she highlighted the importance of shareholder attendance at AGMs, both for voicing support and raising concerns. AGMs also provide an opportunity for executives to present future goals and milestones, giving investors a clear sense of the company's upcoming objectives. With a busy AGM season and several IPOs in progress, Lowe's expertise highlights her commitment to the evolving needs of the finance sector and investor relations. “We're heads down on that right now,” she noted. The IR Department continues to support clients in managing successful AGMs, roadshows, and upcoming IPOs, with plans to attend the JP Morgan Healthcare Conference early next year. #ProactiveInvestprs #IRDepartment #ASX #AGM #AnnualGeneralMeeting #JaneLowe #InvestorRelations #ShareholderEngagement #FinanceSector #IPO #CorporateStrategy #ProactiveInvestors #IRDepartment

The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programming, and we're kicking things off with everyone's favorite life sciences CFO, Allan Shaw. On this episode, Allan shares what's driving the cautious optimism for biotech's return, pointing to factors like December's flurry of M&A activity, interest rate reductions, and easing inflation as just cause for the bullish sentiment that was palpable at the conference. We also discuss what could shift the tailwinds, namely the election year wildcard, and why biotech could benefit from a metered comeback. Come for the facts, stay for the Shawisms!Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

This episode of Moving Forward, Giving Back features the “Reputation Reboot: Steps to Restoring Public Trust in the Biopharma Industry,” panel discussion that took place at the JP Morgan Healthcare Conference on January 9th in San Francisco. The panel brought together several industry heavy-hitters to tackle how we can enhance trust by demystifying our work, sharing empathy and information, and providing opportunities for communities to engage. Introduced by Rob Perez, the Founder and Chairman of Life Science Cares, and moderated by Jim Weiss, the Founder & Chairman of Real Chemistry, the panel includes Ted W. Love, the Chairman of BIO, Julie Gerberding, CEO of the Foundation for the National Institutes of Health (FNIH) and California State Senator Josh Becker.The esteemed group of executives have a multifaceted, dynamic discussion about the general public's perception of the life sciences industry today, the need to increase general awareness of the industry's positive activities in local communities, the importance of actively connecting with all levels of government, as well the impactful actions that organizations like Life Science Cares are doing both locally and nationally. 

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen's next shot at an Alzheimer's treatment. - Why companies can't “muscle their way” into making new molecules. - How NVIDIA could change drug development.  - Moderna's vaccine strategy Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX Host: Deidre Woollard Guest: Karl Thiel Producer: Ricky Mulvey Engineer: Tim Sparks Learn more about your ad choices. Visit megaphone.fm/adchoices

Editor in Chief Jonah Comstock is back from San Francisco where he attended the annual JP Morgan Healthcare Conference. On today's episode, guest host Eloise McLennan interviews Jonah about what he saw and heard at the show.  

Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day two: AI, cell and gene therapy innovation and pricing, and the risks of CAR T cell therapy. Join Lori, Greg and Tyler as they discuss what's been top of mind. You can ⁠⁠follow our coverage⁠⁠ as our team adds updates throughout the day. Join us tomorrow for Day 3 highlights!

We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive AI ⁠is still a hot topic including generative AI; M&A and VC funding; and general whiffs of cautious optimism. Join Lori, Greg and Tyler as they discuss what's been top of mind today. You can ⁠⁠⁠follow our coverage⁠⁠⁠ as our team adds updates throughout the day.

New Bristol-Myers Squibb CEO Chris Boerner speaks on the future of the company and plans for 2024 with Bloomberg's Guy Johnson and Alix Steel from the JPMorgan Healthcare Conference. See omnystudio.com/listener for privacy information.

Boeing shares are sinking after an in-flight blowout grounded most of the carriers planes. Jefferies' Sheila Kahyaoglu explains. Plus, the JPMorgan Healthcare Conference kicks off this week. Barclays' Emily Field tees up the event. And, what's ahead for Apple following its worst week to start a year since 1982? Arete Research's Richard Kramer weighs in.

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology's mission is to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Before becoming CEO, Rob served as Chief Medical Officer at Surface. Prior to joining Surface, he led several programs in hematology and oncology at Bluebird Bio, including the anti-BCMA CAR T cell therapy program. Rob received his MD from Columbia University and has received extensive training in hematology and oncology at top institutions including the University of California San Francisco, Dana Farber, and Mass General Hospital.Dr. Paul Lammers is the Chief Executive Officer of Triumvira Immunologics. Triumvira is leveraging its proprietary T-cell antigen coupling technology to enhance engineered cell therapy to target solid tumors. Paul has a rich background in biotech management, having served as President & CEO at Mirna Therapeutics and Chief Medical Officer and Head of US Product Development for EMD Serono. Paul received his MD from Radboud University in the Netherlands.Hosted by Joe Varriale.

SPECIAL EDITION: BOB@JPMFlagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

SPECIAL EDITION: BOB@JPMBolt Biotherapeutics CEO Randall Schatzman, Ph.D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech, having previously joined us on episodes 14 and 18, respectively. The last time we spoke with Dr. Schatzman, he was preparing the company for its initial public offering. We caught up with him and Dr. Perez at the JP Morgan Healthcare Conference in San Francisco last month for a conversation on the IPO process, the impacts it's had on the go-forward plan at Bolt Bio, the company's clinical progress, and its collaboration strategy moving forward. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Alejandro Dorenbaum is the Chief Medical Officer of Reneo Pharmaceuticals, a clinical-stage company developing drugs for rare mitochondrial disorders. Their lead clinical candidate REN-001 is currently being investigated in the treatment of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). Alejandro is a seasoned biotech executive, having served as Chief Medical Officer at Allakos and Lumena Pharmaceuticals, which was acquired by Shire. Prior to those roles, he held senior positions at Genentech and Biomarin.Amy Grover is Senior Director of Patient Advocacy at Catalyst Pharmaceuticals, a commercial-stage rare disease drug development company with an approved product for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Amy works to ensure that the patient's voice is heard and well-represented. She is a seasoned patient advocate, having served as director of operations and senior manager of patient engagement at Global Genes, a rare disease patient advocacy organization that supports the 7,000 plus rare diseases. Amy led multiple efforts during her tenure at Global Genes, including patient meetups and education, advocacy outreach, communication activities, and overall operations and financial management. Before joining Global Genes, she worked in both the commercial and health insurance industries.Hosted by Joe Varriale.

Hosts Gregg Masters and Fred Goldstein weigh in on select topline takeaways from the 41st JP Morgan Healthcare Conference. In addition to the takeaways, they discuss the current state of population health management and key innovation themes likely to drive the 2023 narrative. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Entdecke die Welt der Aktien mit unserem spannenden Podcast! In jeder Folge analysieren wir die aktuellen Entwicklungen auf dem Aktienmarkt und geben dir wertvolle Investment-Tipps. Im ersten Teil unseres Podcasts besprechen wir die JP Morgan Healthcare Conference, Microsoft, BASF, es gibt ein Update von Companisto, Apple, sowie den Aktienmarkt aus Schweden. Im zweiten Teil geben wir dir einen Überblick über unsere Tops und Flops der Woche. Im dritten Teil, dem Hauptteil, stellen wir dir 13 Investmentideen der US Bank Jeffries vor. Im letzten Teil blicken wir auf die kommende Woche und geben dir zwei weitere Investmentideen. ❌Jetzt ab 250€ in Start-Ups investieren - https://bit.ly/companistomvi ❌Jetzt deinen Basket bei Trading212 erstellen! https://bit.ly/mvit212 mit dem Code VALUE erhältst du nach deiner Anmeldung eine Aktie for free! 1. App Downloaden 2. Verifizieren 3. Code "VALUE" in der "Aktionscode nuten" Sektion eingeben und eine Gratisaktie erhalten ❌ Jetzt SeekingAlpha für 119$ 12 Monate abonnieren! - http://modernvalueinvesting.de/seekingalpha ❌ Jetzt abonnieren! https://modernvalueinvesting.de/abo/

The JP Morgan Healthcare conference is a great place to check the instruments and see how the industry is doing. Today we take a look at what we heard.

Marc discusses the lack of big M&A coming out of last week's JPMorgan Healthcare Conference. Plus, Lecia recaps Bernie Sanders' policy priorities and Jack recounts one TikTok star's struggles to access Ozempic. Also, we end with a chicken salad recipe. Follow us on twitter: @MMMnews www.mmm-online.com

On a special edition of PopHealth Week, co-hosts Gregg and Fred weigh in on select topline takeways from the 41st JP Morgan Healthcare Conference. In addition to topline takeaways, they discuss current state of population health management and key innovation themes likely to drive the 2023 narrative.   ==##==  

Titan International CEO Paul Reitz (TWI) explains the tire-maker's path to profitability. Walgreens Boots Alliance (WBA) paints a vision for the future at the JPMorgan Healthcare Conference. Healthequity (HQY) see rising popularity in health savings accounts. Irhythm Technologies (IRTC) has a potential lifesaving technology for undiagnosed irregular heartbeats. The Drill Down with Cory Johnson offers a regular look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

Marc offers a mini-preview of next week's 2023 JPMorgan Healthcare Conference, and Lecia discusses new legislation that's set to increase access to buprenorphine for opioid-use disorder. Plus, Jack O'Brien tells us what's trending on healthcare social media.

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after positive new data regarding overall survival results in its HER-Vaxx HERIZON study was provided in an oral presentation at the ESMO Asia Congress 2022 in Singapore. Chong also discusses upcoming conferences and investor presentations including the JP Morgan Healthcare Conference 2023 in January in which Imugene has been invited to attend and speak. #ProactiveInvestors #Imugene #asx #biotech #ESMOAsiaCongress #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this minisode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including: our top headlines from the JP Morgan Healthcare Conference (00:32) and the preliminary national coverage decision for Aduhelm from CMS (14:29).Podcast Tags: healthcare, healthcare news, healthcare workforce, gene therapy, whole person health, Medicare Advantage, CMS, Alzheimer'sSource Links:· https://www.bloomberg.com/news/articles/2022-01-12/rna-is-hot-but-mergers-are-not-at-jpmorgan-healthcare-conference · https://www.modernhealthcare.com/finance/reporters-notebook-jp-morgans-2022-health-conference · https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=305 · https://www.kff.org/policy-watch/medicares-coverage-decision-for-the-new-alzheimers-drug-and-why-it-matters/ · https://www.managedhealthcareexecutive.com/view/5-things-you-should-know-about-the-aduhelm-price-cut  For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC. Mindy McGrath, Healthcare Industry Advisormindy.mcgrath@vynamic.comRyan Hummel, Executive and Head of Provider Sectorryan.hummel@vynamic.comJen Burke, Healthcare Industry Strategistjen.burke@vynamic.com

FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss another setback for Biogen's Alzheimer's drug Aduhelm – this time at the hands of the Centres for Medicare and Medicaid Services – and highlight key takeaways from this week's JP Morgan Healthcare Conference.

There aren't many single events that bring together a Who's Who list of the leading private and public companies in biotech and synthetic biology. The JP Morgan Healthcare Conference is one of the rare exceptions. The annual event, held every January, is one of the biggest stages for companies to reveal innovative new products in development, announce acquisitions, and form landscape-shifting collaborations. Investors were left wanting more after the 2021 meeting, which was relatively subdued due to the coronavirus pandemic. The first few days of the 2022 event seemed to live up to historical expectations, with a handful of companies making splashy announcements so far. In this episode of the podcast, 7investing Lead Advisors Simon Erickson and Maxx Chatsko sit down to provide quick takeaways on some of the biggest reveals from the beginning of the 2022 JP Morgan Healthcare Conference. These include: The unveiling of a long-read DNA sequencing technology from Illumina (NASDAQ: ILMN) and an enzymatic DNA synthesis technology from Twist Bioscience (NASDAQ: TWST). Molecular testing leader Exact Sciences (NASDAQ: EXAS) used the stage to reveal that it comfortably beat full-year 2021 guidance and jump into hereditary cancer testing. Meanwhile, Beam Therapeutics (NASDAQ: BEAM) announced a research collaboration with Pfizer (NYSE: PFE) that had an unusual structure. Simon and Maxx also share their thoughts on the slow pace of merger and acquisitions (M&A) in drug development in the last two years — and why record cash balances and a constant need for innovation at the largest companies suggest that could change in 2022. Publicly-traded companies mentioned or alluded to in this podcast include Beam Therapeutics, CRISPR Therapeutics, Eli Lilly, Exact Sciences, Illumina, Intellia Therapeutics, Novo Nordisk, Pacific Biosciences, and Twist Bioscience. 7investing's advisors may own positions in the companies that are mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education: https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing --- Send in a voice message: https://anchor.fm/7investing/message Support this podcast: https://anchor.fm/7investing/support

Athersys CEO BJ Lehmann, Axogen EVP and CFO Peter Mariani and I gathered for a regenerative medicine roundtable discussion in advance of the 2022 JP Morgan Healthcare Conference. 

On day 2 we heard from Mayo, Northwell, Promedica, Prisma, City of Hope, Mass General Brigham, Indiana U, Jefferson Health, Bon Secours Mercy and Spectrum Health. Today we stay on high level themes.

This week, Dexcom CEO Kevin Sayer spoke to the JP Morgan Healthcare Conference about the G7 and beyond. We talk about information from that presentation and get to as many of your questions as time allows. This interview took place on Tuesday Jan 11 and much of what we discussed isn't FDA approved. Dexcom presentation info here Club1921 info here  Our usual disclaimer: Dexcom is a sponsor of this podcast, but they don't dictate content and they don't tell me what to ask their executives. Recent Dexcom episodes: CTO Jake Leach talks about Garmin, Dexcom One & more CEO Kevin Sayer talks about G7, Direct to Watch, Adhesive and more CEO Kevin Sayer talks about Dexcom in Hospital, G7, VA program and more Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below  Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921. Where Diabetes Connections are made This is Diabetes Connections with Stacey Simms. Welcome to another week of the show. You know I'm always so glad to have you here. We aim to educate and inspire about diabetes with a focus on people who use insulin. And I'm talking with Dexcom CEO this week, it's Kevin Sayer, he is back to check in with us again. And in the interest of getting this episode out to you as soon as I could. It might sound a little different right here at the beginning. But Dexcom episodes are always so high interest that it really merits a quick turnaround. I didn't want to sit on this interview for a week. So here's the setup. Dexcom CEO Kevin Sayer gave a presentation to the JP Morgan healthcare conference, if you're listening as this episode goes live, that was just Monday of this week, January 10, the interview you're about to hear took place on Tuesday, January 11. My usual disclaimer Dexcom is a sponsor of this podcast, but they don't dictate content and they don't tell me what to ask their executives. I asked the Diabetes Connections podcast Facebook group for questions. And Whoa, boy, did you have a lot as always not a surprise. And I really appreciate you sending those in, I got to as many as I could, while also trying to include what the folks at Dexcom had really asked me to bring up there are some topics that they wanted Kevin to make sure to address. And I think we do a pretty good job of trying to reach a balance here. Kevin, welcome and Happy New Year, Kevin Sayer 1:46 and Happy New Year to you. Stacey Simms 1:48 Thank you. Well, this seems to have started out in pretty happy way on the headline, just from this week. Dexcom CEO touts unprecedented performance of G7 in clinical trial. This is after your talk at the annual JP Morgan healthcare conference. Tell me a little bit about that unprecedented performance data. Kevin Sayer 2:08 I'm happy to. And I just have to qualify it by saying no, I can't send it to all your listeners at the end of the call yet. We're still waiting for approval in Europe. And we have filed this with the FDA, I'm going to take you back a little bit, we made a decision when we were going through the G7 development process that we wanted to answer that performed better than G6. And all of our scientists looked at us and they go oh, really, you're sure because this is really good. And so we spent a lot of time new algorithms and new manufacturing techniques, there's a lot of things in G7 that make it different. We also wanted to validate that performance with a study that was so large, nobody could refute it. So as you look at the data that I presented at the conference yesterday, over 300 patients 39,000 Match pairs all across since one ranges and on the I CGM standard side, but with the 5% 95% lower bound, and even the absolute points, you can see we are well within all of the iCGM standards, which are very technical and actually are a very good measure of how a sensor actually performs in reality. And they were very thoughtful in developing these standards to try and pick the centers that don't work to put you statistically in a bind to whereby if you really aren't performing in the low range or wherever, you're not going to get that iCGM designation. We're very comfortably there. And the overall MARD in the study, Stacey is eight point, you know I it's in the low eight for adults and pediatrics. And if you start looking at the data, we gather the data sets in three periods, you know, days one and two, the middle days, four, or five and six, and the last days nine and 10. It's pretty low, I think it's below 10. In the first group a day, the first days, which are always a little bit higher, traditionally in our centers than the other days. But in those middle and end days, it's it's near seven, and strips for six. I mean, we have done something that I've been in this business for since 1994. I didn't think we'd ever do this when I started. As far as being this good. This is really, really good data. And we're going to continue to deliver the experience to our customers that they demand from us. So as you can as you think about an iCGM that's driving an automated insulin delivery system. And not only is the performance great, the user where it's 60% smaller, it's a 30 minute warm up. It's a new app. From our perspective, we've got a lot of the clarity data, your listeners will know about clarity. We've got a lot of your clarity data right on the app. There's new alarm configurations. Stacey Simms 4:48 I'm gonna just jump in with a couple of quick clarifications before we go on. You mentioned a number of there that went by quickly I apologize when you talked about the 300 people in this trial 39,000 match what I missed that one Kevin Sayer 5:00 matched pairs. That's where you compare the CGM value to the blood glucose value from the laboratory instrument. So the way our studies work is literally we draw blood samples from the individuals in the study at intervals, and then we actually match the CGM data to that laboratory blood instrument. So 39,000 points from these 300 people in this study were matched. Got it? Stacey Simms 5:27 And you mentioned the MARD mean absolute relative difference. Most of you, as you listen are very familiar with this, the lower the better for CGM G6, I, my understanding was G6 was in the low nines. This is 8.1 for peds. 8.2 for adults, as I'm reading it, that's right. I know you can't tell me I'll ask you anyway, why? What made the difference here? Is it sighs is it algorithm? Do you have anything you can point to? Or is that a trade secret Kevin Sayer 5:49 it's combination, I think the algorithm has been the most, the algorithm changes were really extensive here. And, you know, we always have manufacturing processes to get better, the way we build the G7 centers different in every step of the way. Literally, our G6 manufacturing processes go away and the G7 ones take over the summer, we're a little similar on the actual sensor wire itself, and that manufacturing, but everything else is different. We just think it it's smaller, it's a lot shorter than G6 was. And so it is it's going to be a completely different experience for everybody. Stacey Simms 6:28 So to go back to what you were talking about, before I jumped in there, you were starting to talk about alarms, is there something different for the alarm, Kevin Sayer 6:35 the app is different. And so access to them, and, and just how you use them, if we try to get to be more consumer, thoughtful, as we configured the alarms, we'll see how everybody loves him. It'll be interesting. The alarms are one of the things we get the most comments on when we launch a product initially, we try and please everyone, but we never please everyone. And then you get you know, the agency at one time. I don't know if your call. I think one of our other discussions, we had to make the mute override not work on the low end. Boy, we got a lot of people mad at us about that one. So we've tried to comply with what our users want, and also comply with what the FDA has asked us to do. But I think users will find the alarm experience. Good as well. I like I think it's just gonna be a home run. Yeah, well, I Stacey Simms 7:24 mean, my son would be happy if an alarm never made a noise again. And I know other people who put like it to alarm every time there's any movement. So I hear where you're coming from, can you give any insight into the G7 app in terms of what the differences that we may see as users? And I guess especially one of the questions I always get is about follow any changes of significance coming that you can share follows Kevin Sayer 7:47 on a separate software track. And so the G7 system, the app is just we tried to get more data in the app itself, versus what we have with G6. So a lot of the clarity data, or at least summary query data is sitting there right in your app. And that will be i we think people will like that just to see how they're doing over time you got your time in range data for, you know, three 714, you know, a month, 90 days, see how you're doing time in range wise and the app is other than that it's relatively similar. The startup is different and you know, in the interface is going to be different. I think over time, what you'll see with us is that app is now going to get more sophisticated, we changed the entire software platform for G7 and started over again, and we developed a software platform, we can now really change and add on to a lot easier than we could in the past. And so we're hoping to have more frequent software releases. But we've also learned that CGM is not like Battlestar Galactica game, a game where you want to get a new release every two weeks to fire everybody up. We can't do a release every two weeks, because people depend on this for their, you know, for their lives. And if you do too frequent releases, and you botch a release, you do some wrong, you remember what happened, if we ever make a mistake on the software, the data side, we can't do that. But we do want to add more features more quickly in this platform will enable us to do that. I think one of the things you'll see going forward on the software side, we really want to automate a lot of the tech support features. We've added some, you know, you can get FAQs right from the app now with respect to your sensor, but there are other things we think we can do tech support wise in the app that will you know, reduce everybody's burden. Nobody likes making a phone call and nobody likes picking up the phone. And when we have a sensor fail, and we do have sensors fail, it just doesn't make any sense that you have to call us if we've got data on a phone, it'd be much easier. For example, if we could diagnose that failure right on the app and go through a very quick process to why but where you could get one. I can't give a timeframe when all those things are going to come but the platform is robust enough that over time, we can add features like that. One of the other nice things about G7, since it's fully disposable, you know, every sensor has its own unique serial number. Whereas with G6, that same transmitters used with three months' worth of sensors. So it will be, it will be fun to be able to follow things like that and see how the sensors go through the channel where everybody gets attract things of that nature. So what we're really looking forward to the change in our business that G7 affords us. Stacey Simms 10:28 As usual, I have listener questions, I'm going to try to not repeat because you've been really accessible in the last year, we've talked to a couple of folks from Dexcom, besides yourself. So as you listen, if I didn't get to your question, or if you have a question, good chance, we actually answered it in the last year, year and a half. But given let me ask you about compression lows, because that's one of the things we had talked about, about testing the G7. Any update on that in these trials, if you lay on it, you know, circulation slows, and you can get a false reading any better with the G7 Kevin Sayer 10:54 part of the clinical study is in the compression, because you're pretty much sitting in a chair with a needle in your arm drawing blood. So I'm sorry, we can't really test that we'll learn more about compression when it gets in the field. My hope is that it isn't as much but I can't promise that because I don't know, we're not enough people. I think there are ways over time where we can manage compression better, I'm not going to get into all the science on the phone, believe it or not, I do spend a lot of time with the engineers on this specific issue. Because I have it happened to me from time to time too. So I will call them up say Hey, can we do X, Y or Z? And I think there are some some answers, but I can't give them away because I don't want to give away the playbook. So let's let's just see what we can do overtime on that one. Stacey Simms 11:42 Okay. All right. But you know, the next clinical trial just have them lean against the side of their bed. Kevin Sayer 11:46 We will we'll have to do well. Diffic very scientific. Stacey Simms 11:50 Another question came up, and I think I'm gonna knock wood. I think we've been very lucky on this. It's about new iOS launches from Apple. And I'll read the question and it'll tell you, briefly our experience. This person said Dexcom is part of the Apple Developer Network developers have access to new release such as iOS months before launch, why does Dexcom lag behind Apple iOS launches by months in terms of quote, approved use. And our experience, frankly, is that we have not had any issues Benny and I both have, we just got but as a 13. Plus, we both had very old phones. And we have a latest software and no glitches for us. But that's not everyone's experience, can you talk a little bit about that, Kevin Sayer 12:30 we do get the iOS versions in advance, and we do our best to comply with them, I would I would tell you that it isn't as simple as it's made out to be. And the iOS version that's launched isn't always exactly what we've worked on as they as they make tweaks, not big ones. But you also test for everything that you know about the new iOS versions, and sometimes are things that you don't know, that are in there that come back and may affect the app later on, which is why we delay a little bit, we try and go through every bit of testing that you can imagine. And I'll be honest with your users, Apple's made iOS changes, because of us, we have called up and said, Look, you got to do XY and Z here we have a problem. And they're very good to work with, they've not been difficult at all, you know, when you think about iOS and Android operating system and all the things that they impact. And it's very hard not to impact somebody adversely when you do a new iOS launch. And you know, the perfect example with us is the home you'd override journey that I brought up earlier. In the beginning, I believe the only app that can overcome the mute override within iOS is authorized manna in the beginning was Apple's alarm clock, but other people would go around it with their apps was a medical device, we can't do a go around, we have to make sure what we do is in compliance and known so they work with us very well to make sure we could do what the FDA wanted with respect to the mute button. And the same thing with Android on that, and that was a very difficult exercise. So if there's a delay, it's because we're taking time to see what might have been put into iOS that would change our app. And it just one more thing that will stop. new operating systems are often designed to minimize power usage to extend battery life. Oftentimes, minimizing power usage affects an app that has to be running continuously. And those are the types of battles that we fight are things that we have to make sure we test as a new iOS minimizes power usage. Just does that turn us off? Does it does that stop Dexcom? And we've had, we've discovered things of that nature where it could affect our app. So there you go. Long answers. All right. Stacey Simms 14:44 No, no, that's great. And you mentioned you've asked iOS you've asked Apple to make changes. I assume the alarm was one any others that you can share. Kevin Sayer 14:52 I know that nothing I could share. Nothing major that I like you said they're very cognizant of the Dexcom community there we are. You know, we're we're a very large part of the iOS, you know, we're pretty, it's pretty vocal group when it comes to iOS, Stacey Simms 15:06 pretty vocal group period, the whole community. Alright, we say that with love. So another question came from my group, which was about Sugarmate. This is a, I would describe it as a third party app that uses the Dexcom information. And now the real time API to display and and act on data in its own way, my understanding is that Tandem owns Sugarmate, just from way of background here. And you know, Dexcom owns a little bit of Tandem. So there's a relationship there. Can you speak a little bit about data sources, but the bottom line question here was using Sugarmate and the situation to ask you, does Dexcom feel like they own the patient data? Or do the patients still own their data, even when going through the Dexcom web API's, we believe Kevin Sayer 15:49 the patient's own their data, not us, let me rephrase that we believe the patient's control the use of their data, we are the stewards of that data sitting on our servers. And so we have a responsibility to maintain it and to keep it but where that data goes and where that data is used. We do believe, particularly if it's identified data, that the patient absolutely has complete control over that there's vector sugar made, it's interesting, it was not using API's before it was a like many and non authorized use of the data to display it in a different format that people quite candidly, mess, like better than looking at the Dexcom app. And that's fine. That's why we built the live API's, we made a server change to upgrade our server platform, again, more capacity, more safety, more redundancy. It's a project that's been going on for years. And we've come to the end of that project this year. And when doing so there were some technical issues with Sugarmate, they very quickly switched over to the live API's. And now this is an authorized use of the data based on platform and data pipes that we built. So we're willing to share the data with people when they want it. I think that's an attitude of Dexcom. That changed very much over the years, when we first started, we had a hard time with that concept. Because we worked so hard to invent this technology and gather this data, why would we share it with anybody and say, See, you remember the early days and Nightscout, they were mad at us, we were mad at that. Now, we're not mad at anybody anymore. I think it's important that the data sharing be structured and be used for good purposes. But you know, all in all, it's a, it's a good use of the data that we have, because these are still Dexcom customers. If you want to, you're still buying sensors and using them. It's not a bad thing. Stacey Simms 17:35 Let me ask you a question about the sensors. And this came up in the fall. I've seen it less since but it's still out there. And I don't know if this is something you can answer. But it seems that we have not received this. But it seems that some customers are getting the G6 sensors, the inserters brand new in the original packaging, but a new label on it that says this product meets shelf-life extension requirements. I'm your people I reached out to them in the fall, they told me the stickers, oh, you know, it's all legit. There are updated expiration dates. But I'm curious why this is happening. And you know, what is the shelf life of the G6, Kevin Sayer 18:10 I can tell you exactly what's going on, you do shelf-life testing for product as selling your product will last. And over the course of our product lifecycle, you trying to extend that shelf life through more testing to make sure the product still works for the same amount of time period, if you manufactured product with 12 months shelf life, and then extend that shelf life to 18 months. And it's still the same product and still same manufacturing process rather than unbox it, put it in a new box or throw it away, we put a sticker on the outside because it's same products been tested, it's been proven that it works for 18 months, that's not a problem. That doesn't mean that it's 18 months old, we never have inventory that sits around that long to my knowledge, but we do extend shelf lives, it's important for us to do that, with respect to the distribution channel, particularly as we go to the pharmacy, you know, in the drugstore and and our distributors, the longer they have, you know that they can keep product, the better. We don't want people throwing product away if they don't have to. So all that means is we've extended our testing and shown that the product still works for a longer period of time and wanted to to label the product accordingly. That's all Stacey Simms 19:17 Yeah, I think because it came at a time when there is nervousness just in general not just in diabetes about supply chain and, you know, scarcity concerns. It just seemed unexpected, if that makes sense. Kevin Sayer 19:30 Well I one of the reasons to extend life is in fact supply chain we don't have inventory issues with G6 you know G6 is a very very well running process right now and still, you know, the premier sensor on the market. In fact, we launched a G6 derivation product in Europe, these past three months called Dexcom. One a it's a cash pay product sold on the E commerce platform in four European countries say See now and it's a lower price and geographies. But we did a feature that we took away, share and follow. We're not connecting any devices. It's it's a simpler technology. And again, we have d six supply to be able to go and do things like that. And we are planning to have G7 capacity to do similar things. We are not shooting small on either front will have capacity on both sides. And, you know, listeners on a supply chain perspective, we have been extremely diligent with respect to components for our products. And right now we see things very good today. We my operations team has just been outstanding on this front. So knock on wood, no, no Dexcom problems today. Stacey Simms 20:40 All right, two more questions for you. As always, we're going to run out of time. And as you're listening, I would refer you again, we did have a conversation about Dexcom. One in a previous show. So I will link that up. This one is more of I've asked this, you answered it, but I still continue to get questions to please ask you please make sure when GS seven comes out that Medicare is taken care of? Kevin Sayer 21:00 Well, that is a great question. And I think we've learned from our mistakes in the past. So we will when we get G7 done, what we will do is we will file with CMS to get G7 reimbursement. That's a process that I've heard anecdotally takes three to six months. So if we can get it done in three months, we can't file with CMS until it's approved. But we'll file after approval, and then we'll go and it is our plans to have capacity for all of our US users. When we go it is not that Medicare delay for G6 was one of the most emotionally gut-wrenching things I've dealt with here, because you can't imagine how many emails I got. But we didn't have capacity, and we didn't have everything ready. We've learned from our mistakes. And we'll hopefully be ready to go to everybody. That's our plan right now. Stacey Simms 21:49 That's great. Okay, and my last question is, and I hate doing this to you, but I'm doing it anyways, look into the chapter, we're gonna look, we're gonna come at it sideways, because I did have one listeners and ask him what's planned for the g8? And I said, Come on, let's let him get the G7. Oh, you know what? I'm happy? You can answer that. Let's go for it? Kevin Sayer 22:07 Well, well, I'll give you two because we did lose some time in the beginning because my computer wasn't functioning properly. As we look to the future, we want performance to continue to be better. And then we ask ourselves, but we're getting to the point where as you get to an eight, Mar D, we're getting close to finger six, I don't know how much more of a gap there's going to be, as we look to the future, and even G7 derivatives, we want to go to a longer life, we want to go to 15 days rather than 10. We'll be running studies doing that over the next couple of years. We've got a couple of plans there. We're always looking to upgrade the electronics, and how much better electronics, you know, I know one of your bigger user complaints is connectivity and loss of data, how do we improve that experience for our customers to make that better over time? Because we can always be better. And phones change faster than medical devices? So what why do we put there, we're looking at ways how we can help the environment for future product launches again, and changes in the next platforms, G6 has a lot more materials than G7 does as far as just raw plastic. So how do we make an impact there? On the cost side, there's some form factor things that are pretty far out there that we look at that I won't go into that are really, really fun. We'll see if we had done that. And if they're feasible from a cost of manufacturing perspective, but again, we're now very much focused on customer preference, rather than can't we make this work well enough, you know, in my early days here, it's Can we can we just get this thing working well enough to whereby people can rely on it. Whereas now it's one of those features that are going to make it a more engaging experience. And the last one will be software and analytics and things like that, as I look out over time, do we end up with analytics to whereby we can offer our users a menu of choices on the software side to whereby they can get more if you want Dexcom when don't want to connect or talk to anybody? You can have that if you want something that literally literally analyzes every glucose measurement that you take and does something scientifically. How do you get there, I think there's a number of experiences we can develop over time for future product generations without changing the form factor. So I don't see any slowdown in investment on the r&d side. And on the product side, G6 is the best product out there now and G7 will just be better in every way. And then we just keep going from there. Stacey Simms 24:27 And I appreciate you answering that. Thank you. So if you keep going from there, this is the sideways kind of question I wanted to ask. Okay, go ahead. Okay. A couple of days ago, Abbott announced the idea of what they're calling Lingo, which is bio wearables that will track not only glucose, but ketones and lactate and alcohol. And they say these are not medical devices. You know, this is for people who want to be you know, ultra-marathoners and things like that. We're already seeing sensors used in that way right now. Any plans to do something like this? Kevin Sayer 24:56 You know what our electronics platform for G7 We could put any, if we could develop a sensor wire with membranes and analytes and such for to measure something else, it would fit right into G7. And we design G7. With that in mind, we have advanced technology work going on with the other analytes. But it's still an advanced technology phase, we have to answer a couple of questions. First, have we done all we're supposed to do on the glucose side? Before we run there, and we got a lot to do right now, Stacy, you've heard me talk on this call. And so we need to get done what we started, we need to get G7 launched, we need to scale it up and manufacture it in the 10s. And ultimately, hundreds of millions of products as we stand up a factory in Malaysia and get our Arizona facility built out even more. So we've got to get that work done. The second piece, I'm going to answer this in three pieces. The second piece is what is the commercial opportunity for each of those things. They did announce this line of sensors, but they're all individual sensors. So I've worn a lactate sensor, I'll be completely honest with you from the lab and seeing what it does to my workouts and it's very cool, I can see which workout is better than another one. But I'm not ultra-marathoner, I probably wouldn't change my life. But it was very interesting to look at. There are other scientific uses of black data, particularly in a hospital setting. But what is the market for those, and so we're gonna kind of take an approach, we'll continue to develop the science and if Abbott wants to go develop a market, I am happy to follow this time rather than create it, like we've done with glucose. The third piece of this is there are a lot of biosensors out there. Now, you have your Apple Watch, and Apple is continuing to gather more and more data or ranks, whoop bands, Fitbits, they're advertised on television all the time, I would love to incorporate data from these other sensing technologies into into Dexcom. And vice versa, share our data with those people, particularly as you head down the health and wellness path. And let's get some other people's sensors into our platform. In all honesty, if Abbott's really good at sensing these other things, we'll take that data on our platform and analyze it to if they want to, I guarantee you, that probably isn't gonna, gonna happen. But we would, you know, let's be open about this. We're going to get our glucose work done to because we've not seen an opportunity that exceeds this. Stacey Simms 27:13 Got it? Excellent. Well, thank you so much for answering that it really is so interesting to watch and to see if, as you say, if any of this really, really makes a difference commercially, if people do want to adopt it widely. You know, I think the jury's still out, so we shall follow. Kevin Sayer 27:26 Hey, thanks for having me again. Stacey Simms 27:27 Thank you so much. Have a great day. You're listening to Diabetes Connections with Stacey Simms. More information at the episode homepage, diabetes, Dash connections.com. I'll have the transcription up as soon as I can. But again, quick turnaround on this episode. Thank you so much, again, for sending in the questions. Obviously, I didn't get to all of them. And if you're not in the Facebook group, that's generally where I asked for questions for this kind of thing. It's Diabetes Connections of the group. I'll link it up in the show notes. As always, I know not everybody's on Facebook, please feel free to always email me if you email me now about Dexcom. I'll save those questions until the next time we talk to them. It's Stacey at diabetes connections.com. Again, it's in the show notes and it's on the website. But I get it not everybody is on Facebook these days. To that point, at the very beginning of the show, in that little sponsor tease before things even begin, I mentioned club 1921. So let me tell you a little bit more might be an update for some of you. Maybe some of you are hearing about this for the very first time. Briefly, club 1921 is a website. It's a project I've been working on for a long time. And it is a place where anyone with any type of diabetes can find events anywhere in the United States. We are in beta right now. I invite you to go to the website club 1920 one.com. Until around, check it out. Let me know what you think we've immediately identified we went into beta, late last fall several things mostly about the signup that need to be fixed, those could be fixed by the time you log in, my guess is closer to the end of January. There's a little bit of confusion there. I'll explain in a moment. But other than that, it's pretty well set. The idea here is that instead of a Google Calendar or something like that, this would be a website where you go, you sign up, you tell us what kind of events you're looking for, and then you never have to come back, we'll email you automatically. When events that meet your criteria are edit, very easy. So you pick your type of diabetes, you pick your location, you pick which type of events you want, you pick your age, I mean, you can just say I want everything in every category you can kind of go through, but whatever you pick, and you can change those if you want to come back and change your filters, but whatever you pick, we will email you when those events are added. If you want to add events. There are two types of events you can add one we're very creatively calling events. This is your JDRF walk. This is your friends for life conference. This is your hospital education for people with type two. It's an event by an organization a was a staff an event where they expect lots of people or it's regularly scheduled, or there's a fee, that kind of thing. The other kind of events we're calling Hangouts. These are my favorite types of events. I love what we're calling Hangouts. This is your mom, coffee, your kid play date at a playground, you know, you're going out to a bar, post COVID, with your adult friends with type one, hang outs are not put on by an established organization. They're put on by people like you and me, we don't have a staff, we just want to meet people in our area. When you're adding those. That's where a lot of the confusion came up in the registration process. Because if you want to add events or Hangouts, you actually have to sign up in a different way. So I'm going to talk more about that as the weeks go on. We're fixing that part of the website. But if you try to sign up and you see some confusion, it may be because you are trying to add an event or a Hangout. If you want to just sign up to learn about the events and Hangouts, it should be pretty simple. But if it's not, if you have any questions, any suggestions, please let me know. Email me Stacey at diabetes connections.com. Pretty soon you'll email me Stacey at Club 1920 one.com You're going to be hearing a lot more about this because I'm so excited about it. Yes, I know, we might not have a lot of events this year, that's fine. We're going to have events, eventually, in the diabetes space. Again, we're gonna have lots of events, and social media, Facebook, even things like Eventbrite are a terrible way to get the word out about them. And it shouldn't be work to find them, you should be able to just raise your hand and say, I want to know about this stuff. And it should automatically come to you. And that's what I'm hoping to do here. Okay, back to our regular schedule with the podcast. We will have our Wednesday in the news that's live at 430. Eastern on Wednesday on YouTube and Facebook, and then 445 on Instagram. And then that turns into an audio podcast episode for Fridays. And hopefully next week, we're back to Tuesday and Friday. And we won't do any of this nonsense of pushing episodes around. But I do appreciate your patience. Again, I didn't want you to wait a week for this interview. All right, thank you as always to my editor, the very flexible and understanding John Bukenas from audio editing solutions. And thank you so much for listening. I'm Stacey Simms. I'll see you back here in just a couple of days until then, be kind to yourself. Diabetes Connections is a production of Stacey Simms media. All rights reserved. All wrongs avenged

The non-profit track. Sounds boring, but that is the sacrifice I make for my listeners. 9 hours in front of my computer to find the information that will benefit you. Today we touch on the themes from day 1.

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the biopharma news of their radars this week and look ahead to next week's JP Morgan Healthcare conference, which due to the pandemic will take place virtually for the second year in a row.

As 2021 fades into the history books, it will be remembered as one with exuberant IPOs, punishing aftermarkets, and a lingering pandemic that once again is turning the annual JPMorgan Healthcare Conference into a virtual event. We continue our annual tradition of sitting down with STAT Senior Writer Adam Feuerstein to discuss the year that was in biotech, the best and worst CEOs of 2021, and what's ahead in the new year.

Parabéns a cidade de São Paulo, no episódio de hoje falei do case da Adidas, um tênis 100% reciclável, você usa e depois devolve para virar um novinho.A Boston Scientific compra a Preventice Solutions de sensores cardíacos e a TalkSpace uma empresa que quer democratizar a terapia abrirá o seu capital de olho na onda que viveremos de saúde mental.Você conhece a Vaccination Credential Initiative? É o projeto de grandes empresas para criar uma credencial de status de imunização para todos, de maneira a cruzar todas as informações.E por fim, os 3 principais insights do evento de investidores em Healthcare do JP Morgan:1. Agora eu sou digital2. Parceria para ser ágil3. Evite o momento Kodak

January 22, 2021: Rob DeMichiei, Board Director, Strategic Advisor and Former CFO lends Bill his wisdom and expertise in dissecting the JP Morgan Healthcare Conference. What did they hear and what are the implications moving forward? Social determinants of health is a key area of focus and investment. How can this issue be addressed? Who are the new entrants into healthcare? Will CVS, Walmart and Amazon be the biggest players? What’s going on in the financial reports of health systems right now? What do you do with a workforce that is fatigued from the demands of COVID? Can we get the pre-pandemic volumes of people back in? Or has the model completely changed?Key Points:Health systems employee satisfaction surveys are showing a 10% rise. Employees like the flexibility of working from home. [00:05:40] From a balance sheet standpoint and a liquidity standpoint, the takeaway from the conference is that health systems are still in very good shape [00:07:15]You've got to pull that Cares Act funding out to see where you really stand from a true volume, less volume slash revenue, less expense standpoint.Ascension’s horizontal integration plan [00:09:20] Price transparency is the first crack in the dam. Over the coming years, there will be more disclosure and more transparency. And once brokers, insurers and employers get a hold of this data it's going to lead to lower prices for providers. No doubt. [00:33:20] Fee for service is a brutal paradigm to be in [00:38:40] JP Morgan Healthcare Conderence

Diversity, Equity and Inclusion and Health Disparities were front and center at the JP Morgan Healthcare Conference. A small sample.Health Disparities"While African-Americans comprise of only about 14% of the state's population, they comprise 40% of the deaths related to COVID 19, the state of Michigan." Henry Ford Health System"We have two times the rate for hypertension in our African-American population than we do in our Caucasian". Advocate-AuroraDE&I"Our board approved our 2021 KPIs, which include improving workforce diversity, specifically racial and ethnic diversity for leadership and improving access to care in all the communities where we serve as part of our board recruitment process, we added two wonderful board members to SSM health. They bring racial diversity and tremendous gifts and talents and depth to our dialogue perspectives and work. We added diversity training, exploring unconscious bias for our leaders. We address that in every one of our leadership council meetings. Over the course of the year, we updated our socially adjust wage policy and recently implemented a new minimum wage across our system, which affected directly 1700 of our employees." SSM HealthMore on Today's podcast.

Today's latest headlines from Quick News Daily include news from Moderna, information about possible new US COVID strains in Ohio and the South African variant, and why Jack Dorsey and Mark Zuckerberg did too little too late. Also discussed are the start of the WHO's COVID origins investigation and Andrew Yang's entrance into the race to become Mayor of New York City. Find other podcast players where you can listen to Quick News Daily.----more----SourcesTwitter | Instagram | Facebook Transcript (mostly accurate):First segment excluded so the subject of this portion of the show cannot find it as easily. MODERNAI guess the Moderna CEO is out on a media tour for some reason because he made some more notable comments at another conference. This time, it was at the JPMorgan Healthcare Conference.As for his notable comments, they were that he thinks COVID will be around forever. He said, “We are going to live with this virus, we think, forever”.Viruses that are around continuously, like the flu and the common cold, are called “endemic viruses”. I just thought I’d put that in there in case it’s a trivia answer or you want to sound smart some time.This actually led me down a rabbit hole, because this CNBC story had links to new information on the South African virus, as well as 2 possible new strains that researchers found that originated in the US.For the potentially new US strains, it’s the same old story we’ve been hearing: the mutations seem to be making COVID more contagious but have no effect on how deadly it is or how well the vaccine will work.One of the strains has only been found in one patient, which is pretty crazy. They said that this one had a mutation that’s identical to the UK one, so it made me wonder “are you guys not seeing this? It’s in one person and it’s identical to the UK one? Maybe it’s just the UK one?”As for the South African strain, it’s spread to a couple of other countries now: the UK, France, Switzerland, Japan, Austria, and Zambia.The UK Health Secretary said “I’m incredibly worried about the South African variant, and that’s why we took the action that we did to restrict all flights from South Africa. This is a very, very significant problem…and it’s even more of a problem than the UK new variant”. That’s scary enough in itself, but he just didn’t explain why he said any of this.Thankfully, Dr. Scott Gottlieb (he’s the former CDC Director that I trust most) said that the South African one is concerning him because it seems to be rejecting antibody drug treatment. So, technically, it could become more deadly. But, for what it’s worth, the CDC still says there’s no evidence that it causes more severe illness or that it’s more deadly.  Since this is the common pattern we’re seeing (every single new strain is more contagious but not more deadly), I just have to ask: are all of these mutations helping it spread more quickly, or are these changes actually not doing anything in terms of how easy it is to spread and it’s spreading more quickly because people are being dumb and getting tired of COVID rules?Obviously, there are changes to the virus because it’s been confirmed by its genetics, but is it actually just some coincidence that it’s spreading quickly and they happened to catch the new strain when they test?  The other interesting thing that was in this story about the US variants was about calling these the “UK variant” or “South African variant”. Now that I think about it, it’s probably just trying to shake the blame now that the US might have variants, but some expert in the article said that it’s not really fair to call the variants by where they’re from because it really could have started in another country that isn’t as advanced and isn’t looking for mutations, and it wasn’t found until it reached a country that was more scientifically well-equipped. BIG TECHOne of my favorite podcasts to listen to, The New Abnormal with Molly Jong-Fast and Rick Wilson, had a great guest on the last episode. The guest was Scott Galloway, who’s a professor at NYU and, apparently, an expert in the world of big tech. The great part was him explaining why Twitter CEO Jack Dorsey isn’t some hero for finally banning Trump, permanently, or why Mark Zuckerberg isn’t a great guy, and what Congress can do about all this.One of the best quotes was when Galloway said “There is nothing noble, there is nothing patriotic, there was nothing civic in Zuckerberg or Dorsey kicking these people off of their platforms. This is them trying to wallpaper over their delay and obfuscation. People who get DUIs typically have driven drunk 200 times before they kill a family or they’re pulled over, and these guys have been driving drunk and all of a sudden, a family got killed, and now they’re sorry. They deserve zero f’ing credit for doing the right thing in the bottom of the ninth inning.” He said that their change of heart in banning people is a direct result of Democrats winning the Senate, and Dorsey and Zuckerberg realizing that now that Democrats are running things, their companies could be broken up through antitrust lawsuits from the Justice Department.People are saying that there’s blood on Trump’s hands since 6 people have died from that event, but really, a white supremacist killed a protester in Charlottesville way back in 2017. They also didn’t do anything when Trump said, “when the looting starts, the shooting starts”. The CEOs didn’t decide to kick Trump off until they saw that Mitch McConnell wasn’t going to be majority leader anymore.Galloway also suggested that there needs to be a “perp walk” for these CEOs (a perp walk is the walk you see on TV when the cops bring the perp to the station in handcuffs in front of all the media so that they’re caught on camera. It’s meant to humiliate and shame them). I think he’s right, honestly. He gave a good example: if someone calls a celebrity and says “I can get your kid into Harvard if you give me $50,000”, the celebrity isn’t going to do that anymore because they perp-walked Aunt Becky (Lori Loughlin) and threw her in prison for a couple months. If some CEOs and/or board members of these social media companies get punished for what they’ve let happen on their sites, then other companies will start to shape up.He also explained Section 230 that we’ve been hearing a lot about. He said that it was originally designed to protect smaller companies who didn’t have the budget to monitor the content from other people on their platform.He suggested should move back to that where it’s just for companies who make less than some amount of money, so Twitter, Facebook, YouTube, etc. would have to monitor what’s on their site, and some small startup (who doesn’t have the same amount of resources, like Quick News Daily) wouldn’t.They already can, but they just don’t want to. He gave an example for YouTube, and I’ve experienced it firsthand: when I post my shows to YouTube, almost as soon as it’s posted, I get a copyright notice from YouTube because I use that 2-second clip from that song from Hamilton *play Never Gon’ Be President*. That one. They also get me for playing the 1812 Overture from V for Vendetta at the end of my shows. The 1812 Overture is public domain because it was made before like 1920, but I like the version from V for Vendetta the best, so I use that one. However, I guess that’s copyrighted, so if I made any money on my YouTube videos, that money would go straight to the composer of the V for Vendetta soundtrack.The point of that long example is to show that if YouTube’s AI algorithms can find a 2-second clip of a song from Hamilton in my video, they can find a bunch of right-wingers planning to storm the Capitol or kidnap the Governor of Michigan, it’s just that they don’t want to. COVID INVESTIGATIONExperts from the World Health Organization are due to arrive in China today/yesterday to investigate the origins of the coronavirus. They’ll meet with their counterparts from China, and the big question is whether they’ll visit Wuhan, which is ground zero.This is notable because China is suffocating (figuratively) anyone trying to research the origins of the virus. Sure, people can research it, but if you want to publish the data or findings, it has to be approved by this brand-new task force that’s managed by China’s Cabinet. China’s Cabinet is directly commanded by, who else, Chinese President Xi Jinping. So, when it comes down to it, that means that research that is published is questionable at best.In case you’re wondering what the Chinese people are hearing on their TVs, state media has resorted to pushing conspiracy theories that say the virus is actually from somewhere else, so that’s healthy.This secrecy almost certainly led to warnings coming too late, not enough information getting to the World Health Organization, and slowed down testing early on.Now, hopefully, we’ll be able to settle where this came from once and for all. Was it just someone eating an undercooked bat or pangolin? Were they studying coronaviruses in bats and then it accidentally got out? Reputable scientists say that it almost certainly came from bats and got to us through an intermediate animal that they eat from the wet markets over there, but the right-wing theory is that it was a weapon that got out. I can’t remember if I said it on the podcast, but I think it came from a bat because of a crazy dream I had. Maybe I’ll revisit that when the WHO finishes their investigation (or sooner since that could be a while).ANDREW YANGThursday morning, former Democratic presidential candidate Andrew Yang officially joined the race to become Mayor of New York City.Yang has already been criticized for his lack of engagement in the city's civic and political life before deciding to run for mayor. He’s also going to be cast as “out of touch”, and he made some comments in a recent interview that will give his critics some ammo when it comes to that, be he has lived in NYC since 1996. 

Special panel edition of the Amplifying Scientific Innovation Video Podcast that will focus on innovative approaches for optimizing clinical trial diversity during the JP Morgan Healthcare Conference, which is the largest and most informative healthcare investment symposium in the industry. Moderated by Dr. Sophia Ononye-Onyia, Founder and CEO, The Sophia Consulting Firm. Panel lineup: Mr. Bert Bruce is the Regional President, North America, Rare Disease at Pfizer, one of the world's premier biopharmaceutical companies Dr. Gary A. Puckrein is President and Chief Executive Officer of the National Minority Quality Forum (formerly the National Minority Health Month Foundation), a not-for-profit organization that he founded in 1998 with the goal of strengthening the capacity of local communities to eliminate the disproportionate burden of premature death and preventable illness in minority populations. Mr. Craig Lipset is an Advisor and Founder of Clinical Innovation Partners and former Head of Clinical Innovation at Pfizer. Ms. Janet Lynch Lambert is the CEO of the Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to regenerative medicines and advanced therapies. Dr. Mimi Huizinga is the VP and Head, US Oncology Medical at Novartis Oncology, a leading global medicines company that is reimagining medicine to improve and extend people's lives.

Special panel edition of the Amplifying Scientific Innovation Video Podcast that will focus on innovative approaches for optimizing clinical trial diversity during the JP Morgan Healthcare Conference, which is the largest and most informative healthcare investment symposium in the industry. Moderated by Dr. Sophia Ononye-Onyia, Founder and CEO, The Sophia Consulting Firm. Panel lineup: • Dr. Craig Tendler, VP of Clinical Development and Global Medical Affairs, Oncology at Janssen Research and Development, LLC , one of the Janssen Pharmaceutical Companies of Johnson & Johnson. • Mr. Brian Loew is the CEO of Inspire. • Ms. Kimberly Richardson is a seven year survivor of ovarian cancer who was recently diagnosed with triple-positive breast cancer. • Dr. Carmen Guerra is an Associate Professor of Medicine, Vice Chair of Diversity and Inclusion in the Department of Medicine and Associate Director of Diversity and Outreach at the Abramson Cancer Center (ACC) at the Perelman School of Medicine, Penn . • Dr. Del Smith is the co-founder and CEO of Acclinate.

Dan Michelson’s recap of the JP Morgan Healthcare Conference in Becker’s Hospital Review has become a must-read over the past few years – whether you attend the conferences or not. Dan’s organization, Strata Decision Technology, works with more than 1,000 hospitals from hundreds of health systems on their financial planning, analytics and performance. And as CEO, he has a unique view across systems that allows him to neatly unpack and bring clarity to the various sessions and conversations that occur throughout the JPM conference.Dan’s insight is especially welcome when it comes to the conversations that happen in the secluded confines of the thirty-second floor of the Westin St. Francis Hotel during JPM week. That’s where dozens of CEOs and CFOs from the nation’s largest health systems gather to hear presentations from their peers about high-level strategies in this rapidly changing market. If you’ve read Dan’s articles and wondered how he got started writing them, or if you’ve wanted to hear directly from him with more context on his thoughts, here is your chance. In this episode of Healthcare is Hard, Keith Figlioli’s conversation with Dan brings his JPM recap to life. This year, based on all the provider presentations and many one-on-one conversations, Dan outlines the 10 questions that health systems should be asking and answering to guide the future of their organizations. He and Keith take a deep dive into these questions, discussing topics including:Performance. Looking at whether a leadership team should spend their time focusing on performance or building a budget is one of the important questions Dan outlines for health systems. He explains the choices systems have in more detail, using OSF Healthcare as an example. The Peoria, Illinois-based provider shifted away from traditional budgeting processes in favor of a rolling approach and according to Dan, saved 20,000 hours of leadership time and more than $1 million in spend.Market share. Dan says providers need to change their mindset and think differently about how they define market share as healthcare evolves. In addition to the “share of cup” analogy Dan explained in his written recap, he talks about his experience hearing Walmart’s head of healthcare discuss the retail behemoth’s view of the market. While providers believe they own the patient relationship, he points out how only half of Americans say they have a primary care provider and among the other half, two-thirds haven’t visited their primary care provider in years. With that data, what does Walmart have to say about the market and the patient-provider relationship? “Alright, we’ll take the other 84%.”The “other five” questions. While Dan’s article framed the ten questions providers should be asking, Keith calls him to task for adding another five at the end of the piece without full explanations. Dan says his point is that the ten specific questions health systems are asking themselves doesn’t really matter; what really matters is that they’re asking tough questions like these at the executive level. However, he explains why he thinks questions about affordability are the ones that leave health systems most exposed right now. To hear Dan and Keith’s conversation, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

M&A, the FDA, and an empty elevator. In this bonus episode, C&EN reporters Ryan Cross and Megha Satyanarayana share their takeaways from their time at the J.P. Morgan Healthcare conference a few weeks ago. Read more about JPM 2020 here: https://cen.acs.org/business/investment/JP-Morgan-Healthcare-Conference-slow/98/i3 Image credit: Credit: Megha Satyanarayana/C&EN

This week, Richard Williams, R.Ph., Senior Vice President of Pharmaceutical Innovation and Insights at CSI Specialty Group, joins host Andrew Maddigan, Vice President, Client Engagement, to recap key takeaways from January’s 38th Annual J.P. Morgan Healthcare Conference from San Francisco, CA. Don’t miss this overview featuring some of the major trends and announcements from industry leaders, emerging tech companies and private equity/investment firms at one of the year’s most influential healthcare conferences.

27 Health System CEO/CFO teams shared their accomplishments strategies and financials at the JP Morgan Healthcare Conference. I took notes just to share it with you. Hope you enjoy.

Founding partner and chief development officer Anne Hancock Toomey spent most of last week in San Francisco at the annual JP Morgan Healthcare Conference. And, like most of the 50,000 healthcare executives in town, she never set foot in the Westin for the actual conference. Instead, she spent 16-hour days traversing the hills of San Francisco to meet with those who are otherwise busy delivering superior healthcare, disrupting an antiquated model or financing and advising those in either of the former groups. It was exhilarating (and, yes, exhausting) to break bread with some of the brightest minds in healthcare. In nearly every conversation, she asked healthcare executives the same question: In 2020, what’s one offensive move health systems and providers should make and what’s one defensive move they must make given the headwinds and call for transformation in the industry? Their feedback grouped nicely into a handful of themes: taking cost out of the system, focusing on the consumer experience, forging smart partnerships upstream and down and scale, scale, scale. Here, Hancock Toomey and CEO David Jarrard discuss what she heard.

The Dow closed up 33 points with all three major indices hitting record highs, and Cramer’s breaking down today’s biggest headlines. Then, over the past four years Dexcom’s stock has more than quadrupled, so could the strong trend continue? Cramer’s sitting down with the company’s CEO. Then, last year at the JPMorgan Healthcare Conference, Cramer spoke with Medtronic’s CEO about some short-term headwinds that Wall Street didn’t like. Since then, the stock has skyrocketed and tonight Cramer’s getting an update from the CEO. And, has the market gotten too complacent? Cramer’s going ‘Off the Charts’ on the VIX to make sense of the fear gauge as the market continues to hit record highs.   Learn more about your ad choices. Visit megaphone.fm/adchoices

How does the world’s largest producer of medicines in terms of volume balance the science and the business of innovation? How does an enterprise at such vast scale make decisions about what to build vs. buy, especially given the fast pace of science today? How does it balance attitudes between “not invented here” and “not invented yet”?Vas Narasimhan, CEO of Novartis, sat down with a16z bio general partners Jorge Conde and Vijay Pande, and editor in chief Sonal Chokshi, during the JP Morgan Healthcare Conference around this time last year, to discuss the latest trends in therapeutics; go to market and why both big companies and bio startups need to get market value signals (not just approvals!) from payers earlier in the process; clinical trials, talent, leadership, and more in this rerun of the a16z Podcast. image: Global Panorama/ Flickr

Sean Duffy, Co-Founder & CEO, Omada Health Sean Duffy is the co-founder and CEO of Omada Health, a digital behavioral medicine company dedicated to inspiring and empowering people everywhere to live free of obesity-related chronic conditions like heart disease and type 2 diabetes. In 2017, Omada was recognized as one of Fast Company's World's Most Innovative Companies and in 2016, the company was named a Technology Pioneer by the World Economic Forum. Sean's past speaking engagements include the World Economic Forum annual conference, Clinton Global Initiative Health Matters Summit, the Society for Behavioral Medicine, the JPMorgan Healthcare Conference, and others. He has written extensively about digital health and the future of healthcare in The New England Journal of Medicine, The Wall Street Journal, Forbes, and TechCrunch, among other publications. Prior to Omada, Sean worked at both Google and IDEO. A former MD/MBA candidate at Harvard, he holds a BS in neuroscience from Columbia University.

This week, join host and CSI Specialty Group President and CEO Suzette DiMascio, CHE, CMCE, CPC, as she recaps her key takeaways from January’s 37th Annual J.P. Morgan Healthcare Conference from San Francisco, CA. Don’t miss this quick overview featuring some of the major trends and announcements from industry leaders, emerging tech companies and private equity/investment firms at one of the year’s most influential healthcare conferences.

Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included the FDA commissioner discussing boosting drug competition; BMS offering details on its acquisition of Celgene; and cancer mortality rates declining for the 25th consecutive year. Read more about the stories in this podcast: FDA's Scott Gottlieb, MD, Highlights Biosimilars Initiatives in J.P. Morgan Keynote Address: https://www.centerforbiosimilars.com/conferences/jp-morgan-2019/fdas-scott-gottlieb-md-highlights-biosimilars-initiatives-in-jp-morgan-keynote-address BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference: https://www.ajmc.com/newsroom/bms-celgene-discuss-74-billion-acquisition-during-jp-morgan-healthcare-conference Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens: https://www.ajmc.com/focus-of-the-week/cancer-mortality-rate-drops-for-the-25th-consecutive-year-but-socioeconomic-gap-widens Rise of Marijuana Cries Out for Research, Regulation, Physicians Say: https://www.ajmc.com/focus-of-the-week/rise-of-marijuana-cries-out-for-research-regulation-physicians-say CVS Health CEO Outlines How Aetna Deal Will Benefit Customers: https://www.ajmc.com/newsroom/cvs-health-ceo-outlines-how-aetna-deal-will-benefit-customers

采访 制作丨徐涛 剪辑 校对丨秘丛丛 （以下文字只是音频节目的少许补充。「硅谷早知道」每周周五中午12点准时更新，敬请期待。） 原谅我用了这样一个有「标题党」嫌疑的标题。但这的确是我在这周看到的一个有趣现象。 这周最大的展会，当然是拉斯维加斯的CES。但与此同时，在旧金山还有另一场规模盛大的会议——摩根大通健康医疗峰会（JPMorgan Healthcare Conference）。这场会议中有门票能进入会场的人数在9000人，而进不了场却也依然要在场外开会和社交的人，数目就无法计算了。你只能直观地看到会场周围糟糕的交通，以及周围酒店挤挤挨挨的相关会议。 在旧金山的这场大会中，我发现这里出现的很多投资人之前是投资互联网科技领域。此前他们会在一月初的这个时候去参加 CES，而今年，他们却选择在健康医疗领域捕捉风向和机会。 原因并不难理解。当别的赛道机会变少时，健康医疗领域却依然火热，这让这个赛道吸引来了更多玩家。 举个例子，仅拿中国市场来说，2018年充斥了很多好消息：例如政策正在变好，退出渠道有了更多选择……这都使得整个行业在过去一段时间内变得热门；而我采访的数个投资人和创业者也都说，由于健康医疗是刚需，所以这个行业也并不像别的行业那样容易受到经济周期的影响。 在本期节目，我们请到了摩根大通全球投资银行部中国主管黄国滨先生。他非常清晰梳理了他在这场大会上看到的趋势，以及这个行业中正在出现的机会。 例如他提到，在这次大会上，来自亚洲，尤其是来自中国的参会者正在变多；中国药企在生物制药上的创新表现也非常不俗。 除此之外，他也提到，接下来美国市场上这个行业的并购会变得越来越多，尤其是传统药企都想拥有创新药业务的情况下。 更多详细解读，请在36氪App搜索《硅谷早知道》，订阅并收听这期音频节目，Enjoy！ 访谈嘉宾 黄国滨，摩根大通全球投资银行部中国主管。 提及相关信息 “4+7”带量采购，这是2018年关于药品采购管理最重要的一次变革，对药企影响巨大。具体可以看这篇文章 (https://zhuanlan.zhihu.com/p/52279230)； BMS, (https://zh.wikipedia.org/wiki/%E7%99%BE%E6%97%B6%E7%BE%8E%E6%96%BD%E8%B4%B5%E5%AE%9D)百时美施贵宝(Bristol-Myers Squibb)，成立于美国的跨国制药公司，也是美赞臣和康复宝的母公司； 礼来， (https://zh.wikipedia.org/wiki/%E7%A4%BC%E6%9D%A5%E5%85%AC%E5%8F%B8)Eli Lilly and Company，成立于美国的跨国制药公司 Loxo Oncology， (https://www.loxooncology.com/)其研发的药品 Vitrakvi 对单个基因突变引发的癌症具有明显疗效； Celgene Corporation， (https://zh.wikipedia.org/wiki/%E8%B3%BD%E7%88%BE%E5%9F%BA%E5%9B%A0)赛尔基因，也有译作新基公司，是一家总部位于美国新泽西州萨米特的生物科技公司，主要生产抗癌和消炎药。 相关阅读 健康医疗界的超级碗，能看到哪些新趋势 (https://36kr.com/audio/21854) 药企礼来斥资80亿美元收购同业Loxo，押注癌症在研药品 (https://cn.reuters.com/article/%E4%BC%81%E4%B8%9A%E5%B9%B6%E8%B4%AD%EF%BC%9A%E8%8D%AF%E4%BC%81%E7%A4%BC%E6%9D%A5%E6%96%A5%E8%B5%8480%E4%BA%BF%E7%BE%8E%E5%85%83%E6%94%B6%E8%B4%AD%E5%90%8C%E4%B8%9ALoxo%EF%BC%8C%E6%8A%BC%E6%B3%A8%E7%99%8C%E7%97%87%E5%9C%A8%E7%A0%94%E8%8D%AF%E5%93%81-idCNL3S1Z75IW) 百时美施贵宝斥资740亿美元收购新基 创制药史上最大并购案 (https://cn.reuters.com/article/bristol-myers-qauibb-celgene-ma-0104-idCNKCS1OY056)

Wednesday, March 14th PopHealth Week Features entrpreneur and digital health innovator Sean Duffy. Sean Duffy is the Co-founder and CEO of Omada Health, a digital behavioral medicine company dedicated to inspiring and empowering people everywhere to live free of chronic conditions like heart disease and type 2 diabetes. In 2017, Omada was recognized as one of Fast Company’s Most Innovative Companies and in 2016, the company was named a Technology Pioneer by the World Economic Forum.   An in-demand speaker and thought leader, Sean's accolades include a spot on The San Francisco Business Times’ 2015 list of "40 Under 40," Diabetes Forecast magazine's list of "2014 Diabetes All Stars,” and JPMorgan's list of the "100 Most Intriguing Entrepreneurs of 2014.”   Sean’s past speaking engagements include Clinton Global Initiative Health Matters Summit, SXSW Interactive, the Society for Behavioral Medicine, the JPMorgan Healthcare Conference, and others. He has written extensively about digital health and the future of healthcare in The Wall Street Journal, Forbes, the New England Journal of Medicine, and TechCrunch, among other publications. Prior to Omada, Sean worked at both Google and IDEO. A former MD/MBA candidate at Harvard, he holds a BS in neuroscience from Columbia University. Join us!

In this episode, Michelle Maskaly and Christen Harm speak with Marc O'Connor, chief operating officer at Curant Health, and Pharm Exec's Editor-in-Chief, Lisa Henderson with insights on the JPMorgan Healthcare Conference that took place at the beginning of January. Leadership Tip from Marc O'Connor, chief operating officer at Curant Health.

Sourced from DOCSF 2018Health Innovation Media co-host Nick Adkins @NickisnPDX cathes up with Professor Shafi Ahmed PhD, Fellow Royal College of Surgeons. the 'Virtual Surgeon'.   DOCSF is: Bridging: Technology + Orthopaedics and it's mission is: to unite innovators and health care leaders  to adopt and integrate digital health solutions in musculoskeletal care. Further, the goal of  our alliance is to create meaningful and measurable improvements in quality, cost and access in musculoskeletal verticals. Finally,  DOCSF’s vision is to create a movement that delivers digital health (lower cost, higher quality and better access) by focusing on technology within musculoskeletal care. Organized by the visionary Stefano Bini, MD (@sbiniMD) Founder and Chair, The Digital Orthopedics Conference, and Professor of OrthopaedicsUCSF and hosted during theJP Morgan Healthcare Conference week in San Francisco, the conference brought together physicians, other clinicians, informaticists, entreprenuers, academics, thought leaders, suppliers and vendors with an interest in advancing the deployment and value proposition of technology into the practice of orthopedics. Enjoy!

The 'go-to' investor healthcare conference of the year is the JP Morgan Healthcare Conference held in San Francisco from January 8th = 11th 2018.  in this interview Andre Berger MD, CEO of National ACO a best in class performing Next Generation Model ACO chats with Stephen Bernstein, Global Head of the Healthcare Practice at McDermott, WIll & Emery LLP. Follow on twitter via @McDermottLaw. More about Stephen: Stephen W. Bernstein specializes in e-health, “big data,” deployment of electronic health record systems and health-related matters affected by the internet and the Health Insurance Portability and Accountability Act (HIPAA), as well as private equity investments, mergers, acquisitions, affiliations and joint ventures involving technology, hospitals and physicians. Stephen is the global head of McDermott's Health Practice. Stephen has particular experience working with regional electronic health record collaborations as well as pharmaceutical, biotech, device companies, technology companies, health care providers and insurers concerning uses of health information for clinical and database research, product/disease registries and marketing matters, electronic health record development and implementation, including the ways these endeavors relate to personalized medicine.  Enjoy! 

Trevor and Steve kick off 2018 with the second edition of their JP Morgan Healthcare Conference recap.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care stories included CMS unveiling a new voluntary bundled payment model; coverage from the JP Morgan Healthcare Conference, including immunotherapy's impact on HIV treatment and biosimilars; and news that 2 key diabetes devices will be covered by Medicare. Read more about the stories in this podcast: CMS Tells States How to Require Work for Medicaid: www.ajmc.com/newsroom/cms-tells-states-how-to-require-work-for-medicaid Kentucky First State Approved for Medicaid Work Requirements: www.ajmc.com/newsroom/kentucky-first-state-approved-for-medicaid-work-requirements MedPAC Votes a Resounding "No" to MIPS, Recommends Voluntary Value Program: www.ajmc.com/newsroom/medpac-votes-a-resounding-no-to-mips-recommends-voluntary-value-program CMS Unveils New Voluntary Bundled Payment Model: www.ajmc.com/newsroom/cms-unveils-new-voluntary-bundled-payment-model 5 Things From the 36th Annual JP Morgan Healthcare Conference: www.ajmc.com/newsroom/5-things-from-the-36th-annual-jp-morgan-healthcare-conference Dexcom Works to Bring CGM to the Medicare Population, and More: www.ajmc.com/newsroom/dexcom-works-to-bring-cgm-to-the-medicare-population-and-more Abbott's Freestyle Libre CGM Gains Medicare Coverage: www.ajmc.com/newsroom/abbotts-freestyle-libre-cgm-gains-medicare-coverage Study Shows the Impact Synchronization Programs Have on Medication Adherence: www.ajmc.com/newsroom/study-shows-the-impact-synchronization-programs-have-on-medication-adherence

Welcome back to another episode of Wall Street Unplugged. With the Consumer Electronics Show underway, today I’ve reached out to Marc Lichtenfeld to get a preview of the annual JPMorgan Healthcare Conference. Marc is Chief Income Strategist at the Oxford Club and has covered the biotech field for over a decade. He is my no. 1 analyst when it comes to this industry. With over 400 biotech companies present at the conference, tune in as Marc reveals two companies he’s excited to meet with that have untapped potential... Marc also explains why 2018 is an “inflection point” for the entire sector. Good Investing, Frank Curzio

We conclude our biotech review-preview series with our final installment this week as we take a look at the year ahead as the industry readies for the JPMorgan Healthcare Conference. We spoke to Jon Gardner, U.S. News Editor for EP Vantage, about the EP Vantage 2018 Preview(http://bit.ly/2CT2RDP), the outlook for big-value drug launches, and whether dealmaking or clinical success will drive stock prices in 2018. As a note, this podcast was recorded prior to Spark Therapeutics announcement of its pricing for its gene therapy Luxturna.

Friday, December 1st Fred Goldstein and Gregg Masters dicuss hot topics in the news, including: The Azar nomination to serve as Secretary of Health and Human Services. “He’s a different type of person. He’s got a different experience set than Tom Price,” said Andy Slavitt, who ran CMS under the Obama administration and who has been a bitter and visible critic of the Trump team and their determined efforts to repeal the health law. “There are reasons to want to be hopeful here.” Medicaid Profits California: Whistleblower: Medicaid Managed-Care Firm Improperly Denied Care To Thousands. Optum health group VC fund (all are jumping in) World AIDS Day is tomorrow. Preview of Jefferson College of Population Health, Population Health Colloquium Preview of JP Morgan Healthcare Conference  

Thursday, November 30th Fred Goldstein and Gregg Masters dicuss hot topics in the news, including: The Azar nomination to serve as Secretary of Health and Human Services. “He’s a different type of person. He’s got a different experience set than Tom Price,” said Andy Slavitt, who ran CMS under the Obama administration and who has been a bitter and visible critic of the Trump team and their determined efforts to repeal the health law. “There are reasons to want to be hopeful here.” Medicaid Profits California: Whistleblower: Medicaid Managed-Care Firm Improperly Denied Care To Thousands. Optum health group VC fund (all are jumping in) World AIDS Day is tomorrow. Preview of Jefferson College of Population Health, Population Health Colloquium Preview of JP Morgan Healthcare Conference  

The passage of the 21st Century Cures Act earlier this year catapulted the concept of “real-world evidence” into the spotlight, with many biopharmaceutical companies wondering whether this could be the panacea the industry has been looking for to attain product success. We reflected on this topic with David Thompson, PhD, Senior Vice President, Real-World Evidence Consulting at inVentiv Health, after he moderated a keynote panel at the Biotech Showcase event alongside the popular JP Morgan Healthcare Conference in San Francisco this January. Bottom line, according to Thompson, is that it's complicated – but the fact of the matter is that approval alone no longer gets you to the end zone; more likely, it will get you to the 50-yard line. Appropriate use of real-world evidence can provide some degree of advantage for products entering the marketplace. Listen in to learn more from this discussion on real-world evidence, including why it's so complicated, where the FDA fits in, what it means to payers and how it can impact commercial success. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

At the third annual health 2.0 WinterTech conference running concurrent with JP Morgan Healthcare conference week in San Francisco, Health Innovation Media co-host Jessica DaMassa catches up with Co-founder and COO of RubiconMDCarlos Reines.  Follow on twitter via @Rubicon_MD. The company's about us page notes: 'We were founded in 2013 with a driving vision of democratizing medical expertise so that providers can offer every patient the care they deserve. Three years later, we are furthering this mission with the industry-leading eConsult platform, supported by a best-in-class specialist panel, strategic partnerships, top investors and a smart, passionate team.' For more information on RubiconMD, click here. Produced by Gregg A. Masters, MPH for Health Innovation Media.

Welcome back to another episode of Wall Street Unplugged! It's only January, but if you've followed me for the past few weeks, you've come to realize how important this month really is. I covered one key conference (CES2017) a couple weeks ago. And on today's episode, I have two more coming for you. It's a lot of information in only just a few weeks but bare with me... Each of these conferences come with game-changing announcements. To start, let’s go over what a difference a year makes... Donald Trump is now in office, and the bull market continues to get stronger. In fact, the Dow Jones Industrial Average hit over 20,000 for the first time this week! This “Trump rally” has been strong for investors in every sector… except for one - Biotech. That’s why I invited Marc… Marc is Chief Income Strategist at the Oxford Club, Editor of the Oxford Income Letter and host of the Oxford Club Radio podcast. He just got back from the JPMorgan Healthcare Conference. For those not familiar, the JPMorgan Healthcare Conference its like the Superbowl for healthcare, biotech, and pharmaceuticals. To start off the interview, Marc gives us his takeaways from the event. As Marc explains, the biotech sector has recently been facing a ton of headwinds. The sector currently faces a slew of new regulations as new administration takes the reigns. And in return, the biotech sector got a bit more complex. Although times are rough today, Marc breaks down his opportunistic outlook for the sector going forward. Investors must be patient as we are still in the "early innings" of biotech treatment Marc says. However, he adds that the demand for this sector will explode relatively soon. Together, we then break down the trends and stocks that are going to have the highest impact on the sector. These trends include big data and DNA sequencing. Also, before Marc signs off, he shares with us his favorite growth & income stock outside of the biotech sector. Then, for today's Educational Segment [39:31], I break down my visit to the Vancouver Resource Investment Conference - the largest junior mining conference in the world. The host and close friend, Marin Katusa, invited me to speak at the event. This is where it gets interesting… Out of the 5,000 people at this conference, not one person seemed to be bearish on the resource sector. What does that mean? ...It means I'm nervous. Let's not forget... Only 1 in 3,000 projects go from early stage development to actual production. To make matters worse, some of these stocks are already up 100%-300% from their lows yet people are still doubling their positions! But it's not all bad news. Although about 90% of these companies are terrible long-term investments, a few CEO's I met with were far from bluffing. Tune in as I introduce listeners to the few stocks that caught my attention. One is a stock that could potentially be the next Northern Dynasty!

At the third annual health 2.0 WinterTech conference running concurrent with go-to life sciences, biotech, pharma, medical device and more investor JP Morgan Healthcare conference week in San Francisco, Health Innovation Media co-host Jessica DaMassa catches up with Livzo Co-founders Nataliia Karpenko, CEO and Toni Sicola, Vice President, Corporate Wellness. Livzo provides: 'an innovative health and wellness engagement platform for the workplace and fitness centers'. For more information on Livzo, click  here. Produced by Gregg A. Masters, MPH for Health Innovation Media.  

At the third annual health 2.0 WinterTech conference running concurrent with JP Morgan Healthcare conference week in San Francisco, Health Innovation Media co-host Jessica DaMassa catches up with healthtech expert, author and consultant Shahid N. Shah, CEO of Netspective and FounderHealthcare Guy. Shahid's bio notes he's:  'an award-winning Government 2.0, Health IT, Bio IT & digital Medical Device Inventor & CTO with over 27 years of technology strategy, architecture, engineering, entrepreneurship, speaking, and writing experience.' For more information on Shahid's work see Netspective and Healthcare Guy. Produced by Gregg A. Masters, MPH for Health Innovation Media.

At the third annual health 2.0 WinterTech conference running concurrent with JP Morgan Healthcare conference week in San Francisco, Health Innovation Media co-host Jessica DaMassa extracts the international angle on innovation trends given recent U.S. Presidential Elections from Roberto Ascione, CEO of Healthware International.  According to their website: 'Healthware International: is a global leader in healthcare agency services, Healthware is a unique blend of innovation, advisory, communications & marketing agency services and technology capabilities.' For more information on Healthware International, click here. Produced by Gregg A. Masters, MPH for Health Innovation Media.

In the inaugural “A Healthy Dose” podcast, Trevor and Steve get Ambar Bhattacharyya, Manager Director at Maverick Ventures, Sean Duffy, CEO of Omada Health, and Chrissy Farr, healthcare and technology journalist at Fast Company, together for a roundtable discussion to recap the 2017 JP Morgan Healthcare Conference. The group reflects on the climate of healthcare following the presidential election and the investment trends.

At the third annual health 2.0 WinterTech conference running during JP Morgan Healthcare conference week in San Francisco, co-founder Matt Holt offers his key takeways sourced from the themes and topics generated from a power packed faculty and series of moderated sessions. Health Innovation Media co-host Jessica DaMassa engages this thought leader in a informative and timely conversation. Produced by Gregg A. Masters, MPH forHealth Innovation Media.

With 2016 drawing to a close and the biotech industry gearing up for the annual JPMorgan Healthcare Conference in San Francisco, we continued our holiday tradition of checking in with Adam Feuerstein, senior columnist for TheStreet. We spoke to Feuerstein about the year in biotech that was, the winners and losers of 2016, and what to look for at the JPMorgan Healthcare Conference and beyond.

During the JP Morgan 34th Annual Healthcare Conference Health 2.0 hosts the WinterTech conference which focuses on investment in the emerging digital health ecosystem. In this exchange, Health Innovation Media founder Gregg Masters chats Robin Berzon, MDFounder and CEO Parsley Health; follow on twitter via @parsely_health. Parsely Health is a hybrid 'mashup' of direct practice, consumer focused retail medicine and tech enabled functional medicine that says 'no' to a telephone deferring instead to tech access. For more information click here. Enjoy!  

At Health 2.0 2nd Annual WinterTech Conference Gregg Masters, MPH CEO of Health Innovation Media chats with AthenaHealth CEO Jonathan Bush. For context and details see 34th Annual JP Morgan Healthcare Conference, including free registration for presenting company webcasts and slide decks. For AthenaHealth deck, click here. Enjoy!

On this week's podcast, we spoke about progress for FDA Commissioner-nominee Robert Califf, and a committee report critical of companies and FDA policies over duodenoscope infection outbreaks. We also discussed company updates from the JP Morgan Healthcare Conference, a federal preemption update and CDRH's two-year policy agenda.

Marc Lichtenfeld, chief income strategist at the Oxford Club, editor of the Oxford Income Letter and host of Mark Lichtenfeld’s Oxford Club Radio podcast, shares his best ideas on the upcoming JP Morgan Healthcare Conference that he’ll be attending next week. Marc breaks down the biotech industry.  This is a sector of the market he's been covering for over a decade.  Marc talks about these early stage companies that have huge upside potential. As Mark say’s, “It’s important to keep your emotions in check and your positions sizes small when you’re investing in these startups.” Switching gears Mark gives us his forecast for 2016. You won’t want to miss this.   And finally Mark covers those stocks he looks at for generating safe income. He like the big healthcare companies, especially big pharmaceuticals and he gives us one of his best new recommendations that almost no one else is looking at.